AstraZeneca Pharma announced today that it has received Import and Market permission in Form 45 (Marketing Authorization) from the Drug Controller General of India for durva/umab (lmfinzi™).

The receipt of this Import and Market permission paves way for the launch of this drug in India, subject to the receipt of other related statutory approvals and licenses.

Durvalumab provides a treatment option for patient with locally advance unresectable NonSmall Cell Lung Cancer (NSCLC) and metastatic urothelial carcinoma.

In India, approximately one third of patients with NSCLC are present with Stage III disease and Astra will be the first to bring this immunotherapy for patients.

The stock price rose 5% to Rs.1420 in the morning trades. Its 52-week high is at Rs.1515.40.